Ferini Gianluca, Zagardo Valentina, Viola Anna, Aiello Marco Maria, Harikar Mandara Muralidhar, Venkataram Tejas, Palmisciano Paolo, Illari Salvatore Ivan, Valenti Vito, Umana Giuseppe Emmanuele
Department of Radiation Oncology, REM Radioterapia Srl, Viagrande, Italy.
Department of Radiation Oncology, Fondazione Istituto Oncologico del Mediterraneo (IOM), Viagrande, Italy.
Front Oncol. 2023 Jun 21;13:1146041. doi: 10.3389/fonc.2023.1146041. eCollection 2023.
The rarity of hand acrometastases hampers the consensus-building for their optimal management among the involved oncology professionals. In the current literature, demolitive surgery overcomes the use of palliative radiotherapy, which proved to be ineffective in more than 30% of cases treated with classic palliative dose schemes, carrying also a not negligible radiation-related adverse event rate. Against this background, stereotactic body radiation therapy (SBRT) could emerge as a well-balanced therapeutic option.
Here we describe the methods and outcomes of a SBRT treatment of a painful and function-limiting hand acrometastasis in a patient with a history of stage IIIB lung adenocarcinoma. We delivered a total dose of 30 Gy in five daily fractions to a soft-tissue metastasis abutting the fifth metacarpal bone through the SBRT protocol generally used for intracranial treatments. A few weeks later, the patient reported a clinical complete response with acrometastasis and pain disappearance, function recovery, and no significant toxicity. The acrometastasis was the first sign of an atypical cancer progression.
SBRT for hand acrometastases is feasible and might have the best therapeutic profile among the currently available treatment options for this rare clinical scenario. Larger investigations are needed to confirm the present single-case experience.
手部肢端转移瘤极为罕见,这阻碍了肿瘤学专业人员就其最佳治疗方案达成共识。在当前文献中,根治性手术优于姑息性放疗,事实证明,经典姑息剂量方案治疗的病例中,超过30%效果不佳,且放疗相关不良事件发生率也不容小觑。在此背景下,立体定向体部放疗(SBRT)可能成为一种平衡良好的治疗选择。
本文描述了一名有IIIB期肺腺癌病史患者,其手部疼痛且功能受限的肢端转移瘤接受SBRT治疗的方法及结果。我们通过通常用于颅内治疗的SBRT方案,将30 Gy的总剂量分5次每日给予紧邻第五掌骨的软组织转移瘤。几周后,患者报告临床完全缓解,肢端转移瘤和疼痛消失,功能恢复,且无明显毒性。该肢端转移瘤是不典型癌症进展的首个迹象。
SBRT治疗手部肢端转移瘤是可行的,在目前针对这种罕见临床情况的可用治疗方案中可能具有最佳治疗效果。需要更大规模的研究来证实目前的单病例经验。